Autopsy report · NCT04855136

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

“Business objectives have changed”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 11 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Celgene

Sponsor type

Industry

Conditions

Multiple Myeloma

Interventions

BB2121; CC-220; BMS-986405

Participants

21

Sites

17

Countries

Spain, United States

Trials that died the same way

• Entecavir Plus Adefovir in Lamivudine-Resistant Patients
  “Business Objectives Changed” (97% match in meaning)
• A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
  “Business objective has changed” (93% match in meaning)
• Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
  “(Non-safety reason, business objectives have changed)” (71% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (71% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.